September 15, 2017 10:09 AM EDT

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

Shehla Shakoor

Managing Director

⇨ BioMarin says that the FDA is indicating that it won’t be holding a panel review for pegvaliase as a new treatment for phenylketonuria …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?

FDA takes a pass on peg­valiase pan­el; Flex­ion ter­mi­nates an old As­traZeneca pact

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

FDA takes a pass on pegvaliase panel; Flexion terminates an old AstraZeneca pact

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?